Trial Profile

Safety and efficacy of Tocilizumab for the treatment of Systemic Juvenile Idiopathic Arthritis in children (German BIKER registry)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications Juvenile rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Sponsors Chugai Pharma Europe; Roche

Most Recent Events

15 Jun 2019 Results (n=345) assessing systemic and polyarticular juvenile idiopathic arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
09 Feb 2016 New trial record
11 Nov 2015 Results (n=193) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com